The DOI matches its OpenAlex record; 2 of the 2 references it cites were found in a registry or an index.
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis
Open accessAbstract
OBJECTIVES: To examine whether the increased risk of cardiovascular events with rofecoxib represents a class effect of cyclooxygenase-2 (COX-2) specific inhibitors. DESIGN: Systematic review and meta-analysis of randomized double-blind clinical trials of celecoxib of at least 6 weeks' duration and presented data on serious cardiovascular thromboembolic events. Data sources included six bibliographic databases, the relevant files of the United States Food and Drug Administration, and pharmaceutical company websites. MAIN OUTCOME MEASURES: Pooled fixed effects estimates of the odds ratios for risk of cardiovascular events with celecoxib compared with comparator treatment were calculated using the inverse variance weight method. The main outcome measure was myocardial infarction. RESULTS: Four placebo-controlled trials with 4422 patients were included in the primary meta-analysis comparing celecoxib with placebo. The odds ratio of myocardial infarction with celecoxib compared to placebo was 2.26 (95%confidence interval 1.0 to 5.1). For composite cardiovascular events [odd ratio 1.38 (95% CI 0.91 to 2.10)], cardiovascular deaths [OR 1.06 (95% CI 0.38 to 2.95)] and stroke [OR 1.0(95% CI 0.51 to 1.84)] there was no significant increase in risk with celecoxib. The secondary meta-analysis which included a total of six studies (with placebo, diclofenac, ibuprofen, and paracetamol as comparators) of 12 780 patients, showed similar findings with a significant increased risk with celecoxib for myocardial infarction [OR 1.88 (95% CI 1.15 to 3.08)] but not other outcome measures. CONCLUSION: The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Meta‐Analysis Of Controlled Clinical Trials
Whitehead, A. (2002) · doi:10.1002/0470854200 · Cited by 827
Cited by
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796
OARSI recommendations for the management of hip and knee osteoarthritis
Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.013 · Cited by 1,700
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Pharmacological Management of Persistent Pain in Older Persons
(2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00699.x · Cited by 916
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.06.014 · Cited by 796
Metadata
- Authors
- Caldwell, B. O.
- Venue
- Journal of the Royal Society of Medicine
- Publisher
- SAGE Publishing
- Published
- 2006-03-01
- Volume
- 99
- Issue
- 3
- Pages
- 132-140
- ISSN
- 0141-0768 (ISSN-L)
- OpenAlex
- W2095127972
- Cited by
- 221
- References
- 2
- FWCI
- 17.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1258/jrsm.99.3.132
- The paper
- Caldwell, B. O. (2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. Journal of the Royal Society of Medicine. https://doi.org/10.1258/jrsm.99.3.132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.